InsiderTrades

Form 4 for BIIB Biogen

Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001127602-24-004801 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-13 2024-02-09 BIIB Singhal Priya Head of Development M - OptEx $0.00 +1,212 5,309 +30% $0
D 2024-02-13 2024-02-12 BIIB Singhal Priya Head of Development S - Sale+OE $239.45 -419 4,516 -8% -$100.3K
D 2024-02-13 2024-02-09 BIIB Singhal Priya Head of Development F - Tax $240.98 -374 4,935 -7% -$90.1K
D 2024-02-13 2024-02-09 BIIB Singhal Priya Head of Development M - OptEx $0.00 -1,212 1,212 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-09 M A 1,212 $0.00 5,309.09 D — —
2 Common Common Stock 2024-02-12 S D 419 $239.45 4,516.09 D — —
3 Common Common Stock 2024-02-09 F D 374 $240.98 4,935.09 D — —
4 Derivative Restricted Stock Unit 2024-02-09 M D 1,212 $0.00 1,212 D $0.00 · — to 2025-02-10 1,212 Common Stock (F1) This award was granted to the reporting person on February 10, 2022 and will vest in three equal installments on each anniversary of the grant date.